This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1089/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q58204775
rdf:type
wikibase:Item
schema:description
im April 2006 veröffentlichter wissenschaftlicher Artikel article wetenschappelijk artikel наукова стаття, опублікована у квітні 2006
p:P577
wds:Q58204775-DBBDD145-849E-4305-BD4E-86E4D31E361A
wdt:P577
2006-04-01T00:00:00Z
p:P2093
wds:Q58204775-66468ACE-0BAD-494F-AD54-1D9DED73008F wds:Q58204775-6B1F15FF-EA35-4BA4-BAE6-C40AFA555331 wds:Q58204775-EA7C1429-6CDA-4932-B2D2-11ED1A3829EA wds:Q58204775-E61BF043-2AB2-4EEE-A0B5-D95F6EA86297 wds:Q58204775-1D417FA6-29FC-4246-977A-9A6A021306ED
wdt:P2093
Jaume Mascaró Pere Domingo Josep Cucurull Josep Vilaró Enric Pedrol
rdfs:label
Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients
skos:prefLabel
Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients
schema:name
Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients
p:P50
wds:Q58204775-72390775-9204-4F68-A355-BC90F853D2B9 wds:Q58204775-8B0C1451-11D5-4DDD-976F-DBCF8BFEEAD2 wds:Q58204775-9EAFE1AE-90D1-440D-A028-5A96C811E41D wds:Q58204775-AFCECA6C-3DAD-49B2-BAE7-5BB7316BBDC9 wds:Q58204775-FD8C530D-3AE5-4434-BBF9-3F94560961FC wds:Q58204775-1F566A0D-F83B-4B26-83E2-6A77DF3C16D4 wds:Q58204775-3B775F77-4734-4885-9356-1D72EBC9C974 wds:Q58204775-55582AE1-DB00-457E-A380-AA8F2DD44197 wds:Q58204775-121AB6CB-C3A9-4896-8576-DDB50CB0D4C5 wds:Q58204775-16AAC838-8CE8-4DB2-B1D0-9F83A3531CD2 wds:Q58204775-C95012E3-0436-4023-9877-D592BFC42520 wds:Q58204775-D8E79C2C-3ADC-4F85-ABE9-E93935AA983F
wdt:P50
wd:Q47006512 wd:Q117232551 wd:Q20100355 wd:Q79455500 wd:Q40375640 wd:Q90969790 wd:Q60556297 wd:Q117232550 wd:Q42430889 wd:Q99710544 wd:Q91245582 wd:Q117232552
p:P1476
wds:Q58204775-C7B59FAA-7566-419A-A12F-929504577C06
wdt:P1476
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients
p:P304
wds:Q58204775-C7457A45-AFD7-4685-9F00-789622E5F0F5
wdt:P304
321-329
p:P31
wds:Q58204775-0641F67B-DB11-4EF8-ADBB-35E0A4D9F143
wdt:P31
wd:Q13442814
p:P921
wds:Q58204775-8E83F7C2-0DE6-423D-BA69-7FA0441F8F4F wds:Q58204775-B19AA3CA-19A9-44E4-A856-470039826621 wds:Q58204775-3928FEFE-D97A-425A-8620-7FBF482935F2
wdt:P921
wd:Q101929 wd:Q7215 wd:Q18123741
p:P698
wds:Q58204775-84FA62C1-8E0B-4DE7-89AD-4E1E42744179
wdtn:P698
n9:16623634
wdt:P698
16623634
p:P1433
wds:Q58204775-815F5AF3-E262-4323-857F-FD8A1140F7E9
wdt:P1433
wd:Q4651880
p:P433
wds:Q58204775-F9CD920D-AF29-46AF-AF4F-2A9AFA55C033
p:P478
wds:Q58204775-5E33E636-8468-4A26-8B76-B78058793936
wdt:P433
4
wdt:P478
22
p:P356
wds:Q58204775-479DBDD2-B710-4842-9322-B24F4C8237E4
wdtn:P356
n12:AID.2006.22.321
wdt:P356
10.1089/AID.2006.22.321